Chemoradiotherapy for Limited-disease Small-cell Lung Cancer in Elderly Patients Aged 75 Years or Older (original) (raw)

Abstract

Background: As clinical trials for limited-disease small-cell lung cancer often exclude elderly patients due to comorbidities and a decline in organ function, the most suitable treatment for limited-disease small-cell lung cancer patients aged 75 years or older still remains unclear. Methods: From July 2002 to June 2011, 20 consecutive patients aged 75 years or older, with Stage II to IIIB limited-disease small-cell lung cancer, were scheduled to be treated with concurrent or sequential chemoradiotherapy at the Shizuoka Cancer Center. We reviewed the medical charts of the patients and evaluated their characteristics, treatment compliance, toxicity and antitumor efficacy. Results: Five patients were treated with concurrent chemoradiotherapy and the other 15 patients were scheduled to be treated with sequential chemoradiotherapy. Of these 15 patients, 12 were treated with four cycles of etoposide (80 mg/m 2 , days 1-3, q3-4w) plus carboplatin (area under the curve 5, day 1, q3-4w), followed by thoracic radiotherapy. Of the five patients treated with concurrent chemoradiotherapy, discontinuation of chemotherapy/ thoracic radiotherapy occurred in two patients due to toxicity and they suffered a prolonged decrease in performance status. Of the 12 patients treated with etoposide plus carboplatin followed by sequential thoracic radiotherapy, the response rate, median progression-free survival and median overall survival time were 91%, 244 and 601 days. Conclusions: These results suggest that concurrent chemoradiotherapy is not feasible for all limited-disease small-cell lung cancer patients aged 75 years or older. The alternative of four cycles of etoposide plus carboplatin followed by thoracic radiotherapy is a candidate for the standard treatment of limited-disease small-cell lung cancer patients in this age group. A further trial is warranted to develop and evaluate the optimal treatment for elderly patients with limited-disease small-cell lung cancer.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (19)

  1. Sekine I, Yamamoto N, Kunitoh H, et al. Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. Cancer Treat Rev 2004;30:359-68.
  2. Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. J Clin Oncol 2007;25:1898-907.
  3. Morita T. A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world. Jpn J Cancer Res 2002;93:15-23.
  4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer. http://www.nccn.org/ index.asp.
  5. Sørensen M, Pijls-Johannesma M, Felip E; on behalf of the ESMO guidelines working group small-cell lung cancer. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v120-5.
  6. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054 -60.
  7. Sekine I, Fukuda H, Kunitoh H, Saijo N. Cancer chemotherapy in the elderly. Jpn J Clin Oncol 1998;28:463-73.
  8. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004;22:4626 -31.
  9. Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000;89:1953-60.
  10. Schild SE, Stella PJ, Brooks BJ, et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 2005;103:2349-54.
  11. Mountain CF. Revisions in the international system for lung cancer. Chest 1997;111:1710-7.
  12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst 2000;92:205-16.
  13. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/ctc.htm
  14. Shimizu T, Sekine I, Sumi M, et al. Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older. Jpn J Clin Oncol 2007;37:181-5.
  15. Okamoto K, Okamoto I, Takezawa K, et al. Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients. Jpn J Clin Oncol 2010;40:54-9.
  16. Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide versus split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007;97:162-9.
  17. Murray N, Gratt C, Shah A, et al. Abbreviated treatment for elderly, infirm or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3323-8.
  18. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Carboplatin, etoposide and accelerated hyperfractionated radiotherapy for elderly patients with limited small lung carcinoma. Cancer 1998;82:836-41.
  19. Kies MS, Mira JG, Crowley JJ, et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a southwest oncology group study. J Clin Oncol 1987;5:592 -600.